Results 61 to 70 of about 50,593 (147)

Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy

Biomedicines
Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease, with an estimated prevalence of 1:600 in the general population, and is associated with significant morbidity.
Helin Savsin, Tomasz Tokarek
doaj   +1 more source

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life.
Bryton J. Davis, Hailey Volk, Olives Nguyen, Daniel Kamna, Hongya Chen, Roberto Barriales‐Villa, Pablo Garcia‐Pavia, Iacopo Olivotto, Anjali T. Owens, Caroline J. Coats, Theodore P. Abraham, Scott D. Solomon, Martin S. Maron, Ahmad Masri   +13 more
doaj   +1 more source

Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond

The Egyptian Heart Journal
Background A cardiac condition marked by excessive growth of heart muscle cells, hypertrophic cardiomyopathy (HCM) is a complex genetic disorder characterized by left ventricular hypertrophy, microvascular ischemia, myocardial fibrosis, and diastolic ...
Khadija Sarwer, Saeeda Lashari, Nida Rafaqat, Maher, Abdul Raheem, Muneeb Ur Rehman, Syed Muhammad Iraj Abbas   +6 more
doaj   +1 more source

A Narrative Review of Current and Investigational Therapies in Hypertrophic Cardiomyopathy

Biomedicines
Hypertrophic cardiomyopathy is the most prevalent inherited cardiac condition, distinguished by an autosomal dominant inheritance pattern. Diagnosis can be achieved through echocardiography, cardiac magnetic resonance imaging, and genetic testing ...
Ian Ogurek, Randeep Gill, Vasiliki Tasouli-Drakou, Ronnie Joseph, Arbab Khalid, Nazanin Houshmand, Tahir Tak   +6 more
doaj   +1 more source

Mavacamten Cardiac Myosin Inhibitor: Clinical Applications and Future Perspectives

Cureus
Mavacamten is a first-in-class, selective allosteric inhibitor of cardiac myosin adenosine triphosphatase (ATPase) that has emerged as a novel therapeutic option for patients with symptomatic hypertrophic obstructive cardiomyopathy (HOCM) who remain refractory to conventional therapy, such as beta-blockers and calcium channel blockers.
Ramadan, Mahmoud M, Al-Najjar, Raghad A, Abady, Rokia S, Obaid, Hala A, Mostafa, Yasmeen A, Al-Obeid, Mohammad T, Elmahal, Mohammed   +6 more
openaire   +2 more sources

Breaking the link between morphology and potency for mESCs

Cell & Bioscience
Background In stem cell biology, a long-held structure–function relationship is the domed colony morphology and naïve pluripotency for mouse or human pluripotent stem cells. This link has provided a convenient way to recognize bona fide naïve pluripotent
Yixin Fan, Xiaomin Wang, Ziwei Zhai, Tao Huang, Wei Li, Zechuan Liang, Zhaoyi Ma, Yu Fu, Pengli Li, Junqi Kuang, Duanqing Pei   +10 more
doaj   +1 more source

Two Classes of Myosin Inhibitors, Para-nitroblebbistatin and Mavacamten, Stabilize β-Cardiac Myosin in Different Structural and Functional States. [PDF]

J Mol Biol, 2021
Gollapudi SK, Ma W, Chakravarthy S, Combs AC, Sa N, Langer S, Irving TC, Nag S.   +7 more
europepmc   +1 more source

Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers. [PDF]

Heart Fail Rev
Grupper A, Sverdlov AL, Cheema BS, Nasrollahizadeh A, Hosseini K.   +4 more
europepmc   +1 more source

Role of provocation and exercise imaging for the identification of candidates for cardiac myosin inhibitors. [PDF]

ESC Heart Fail
Erzeel J, Dhont S, van Es M, Ulgar D, Bertrand P, Mullens W, Martens P.   +6 more
europepmc   +1 more source

The ODYSSEY-HCM and MAPLE-HCM studies: the role of cardiac myosin inhibitors in hypertrophic cardiomyopathy (obstructive and non-obstructive). [PDF]

Eur Heart J Suppl
Biagini E, Schiavo MA.
europepmc   +1 more source